Navigation Links
U.S. Study Shows Significant Improvement for Patients Suffering from Excessive Sweating with Topical Antiperspirant
Date:5/15/2009

ALBANY, N.Y., May 15 /PRNewswire/ -- Valeo Pharma announced today a new study recently published that demonstrated the efficacy and safety of Hydrosal(R), a novel high strength topical antiperspirant with 15% aluminum chloride and 2% salicylic acid in proprietary gel base for patients with moderate-to-severe hyperhidrosis (excessive sweating).

The study, conducted by Katherine Flanagan, MD and Dee Anna Glaser, MD at the Department of Dermatology at Saint Louis University School of Medicine, was published in the May issue of the Journal of Drugs in Dermatology (JDD). Of the thirty patients who were enrolled, 43% had tried high-strength antiperspirants previously. Patients were given Hydrosal and monitored at 4 and 12 weeks for efficacy and tolerability. They were instructed to apply a small amount of the gel at bedtime for seven days and twice per week or as tolerated thereafter.

Overall, 70% of participants demonstrated significant improvement with satisfaction of treatment and Hydrosal was well-tolerated with minimal side effects. Patients who had previously failed other high-strength antiperspirants also reported similar success. They also experienced significant improvements in quality of life including improvement in social and professional situations.

"The key to Hydrosal's effectiveness is the gel base -- it is unique and helps balance high efficacy and tolerability for patients with moderate to severe hyperhidrosis. Valeo is extremely pleased that these results have shown a significant improvement in the quality of life for these patients, so they can enjoy activities more and not have to worry about their excessive sweating," stated Steve Saviuk, President of Valeo Pharma.

To learn more about Hydrosal Professional, please visit www.hydrosalpro.com or contact Valeo Pharma at 866 694-0150.

To see press release go to http://myprgenie.com/1897


'/>"/>
SOURCE Valeo Pharma
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Penn study finds pro-death proteins required to regulate healthy immune function
2. New study shows promise in reducing surgical risks associated with surgical bleeding
3. Study, meta-analysis examine factors associated with death from heatstroke
4. Study suggests loss of 2 types of neurons -- not just 1 -- triggers Parkinsons symptoms
5. Study says COPD testing is not measuring up
6. Preclinical study suggests organ-transplant drug may aid in lupus fight
7. Ability to cope with stress can increase good cholesterol in older white men, study finds
8. High alcohol consumption increases stroke risk, Tulane study says
9. Mailman School of Public Health study examines link between racial discrimination and substance use
10. Pitt study finds inequality in tobacco advertising
11. Stanford study highlights cost-effective method of lowering heart disease risks
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/29/2017)... (PRWEB) , ... April 29, 2017 , ... ... celebrate the profession and recognize the positive impact veterinarians have on animal health ... and the World Organization for Animal Health (OIE) choose a theme each year ...
(Date:4/28/2017)... NC (PRWEB) , ... April 28, 2017 , ... ... announce its new partnership with the Home Care Association of America (HCAOA). This ... and Private Duty Accreditation services, as well as discounts on Accreditation University (AU) ...
(Date:4/28/2017)... (PRWEB) , ... April 28, 2017 , ... Beginning in ... of their formulas. This begins with the popular ClearLungs Extra Strength formula. To ensure ... changing the formula in the following ways:, , Removal of ...
(Date:4/28/2017)... ... April 28, 2017 , ... ... distribution of the GlycoMark test throughout the Northeast U.S. , GlycoMark is ... with diabetes. The GlycoMark test provides a clinically proven one- to two-week measure ...
(Date:4/28/2017)... Fairfax, VA (PRWEB) , ... April 28, 2017 , ... ... elected volunteer board members and officers for 2017-2018. The annual board election process has ... serving on a volunteer basis. , Thomas C. Dickerson, Ed.D., FACHE, succeeds Jim Hamilton, ...
Breaking Medicine News(10 mins):
(Date:4/20/2017)... MINNEAPOLIS , April 20, 2017  Cogentix ... company focused on providing the Urology, Uro/Gyn and ... reported that Ash Keswani has joined the Company ... In this newly created position, Mr. Keswani will ... and CEO. "Our organization is delighted ...
(Date:4/20/2017)... Research and Markets has announced the addition of the ... Market and Increasing Usage of Complex Biologics during the Forecast Period" ... ... 20 Billion in 2015 to around USD 26 Billion by 2020. ... by Rapidly Expanding Injectables Market and Increasing Usage of Complex Biologics ...
(Date:4/20/2017)... 20, 2017 Eyevensys, a private ... non-viral gene expression technology that enables the safe, local, ... address a wide range of ophthalmic diseases, announces it ... products Regulatory Agency (MHRA) to advance its technology into ... ...
Breaking Medicine Technology: